BridgeMD
STRIDES - A Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia
EU CTIS ID: 2022-501004-10-00
What this study is testing
Determine the efficacy of SLS-005 0.75 g/kg for the treatment of spinocerebellar ataxia type-3 (SCA3) in adults
- Phase II and Phase III (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 1. Signed informed consent.
- 2. Men and women, 18 to 75 years (inclusive) of age.
- 3. Clinical diagnosis of SCA3 with documented genetic confirmation.
- 4. m-SARA total score ≥ 4 at the screening visit.
- 5. m-SARA gait component score ≥ 1 at the screening visit.
- 6. Body Mass Index (BMI) between 18 kg/m2 and 35 kg/m2 (inclusive).
You likely can't join if
- 1. Any hereditary ataxia that is not genetically confirmed to be SCA Type 3, or any type of ataxia that is acquired or secondary to another medical condition including but not limited to, alcoholism, head injury, multiple sclerosis, olivopontocerebellar atrophy, multiple system atrophy, or stroke.
- 10. Prior history of drug-induced liver injury (DILI) and/or laboratory results at screening that indicate inadequate liver function (e.g. alanine aminotransferase [ALT], aspartate aminotransferase [AST], gamma-glutamyl transferase [GGT] > 2 times the upper limit of normal [x ULN] and/or total bilirubin level > 2 x ULN).
- 11. Laboratory results at screening that indicate inadequate renal function (e.g. estimated creatinine clearance of < 60 mL/min calculated by the Cockcroft and Gault formula).
- 12. Any current cardiovascular disease or abnormality on 12-lead ECG at screening that, in the investigator’s opinion, is clinically significant and could be a potential safety risk to the participant.
- 13. Any current psychiatric, neurological, or cognitive disorder that, in the investigator’s opinion, may interfere with the participant’s ability to provide informed consent or appropriately complete the study’s safety or efficacy assessments.
- 14. Significant suicide risk as indicated by a “yes” response to question #4 or #5 under Suicidal Ideation in the past 6 months or any “yes” response under Suicidal Behavior in the past 3 years on the Columbia Suicide Severity Rating Scale (C-SSRS) during the screening visit.
See the full eligibility criteria
Who can join
- 1. Signed informed consent.
- 2. Men and women, 18 to 75 years (inclusive) of age.
- 3. Clinical diagnosis of SCA3 with documented genetic confirmation.
- 4. m-SARA total score ≥ 4 at the screening visit.
- 5. m-SARA gait component score ≥ 1 at the screening visit.
- 6. Body Mass Index (BMI) between 18 kg/m2 and 35 kg/m2 (inclusive).
- 7. Stable doses of all concomitant medications for at least 30 days prior to the screening visit.
- 8. Negative serum beta-human chorionic gonadotropin (ß-hCG) pregnancy result at the screening visit for female participants of childbearing potential.
- 9. Willingness to comply with sexual abstinence or contraception guidelines of this study.
What rules you out
- 1. Any hereditary ataxia that is not genetically confirmed to be SCA Type 3, or any type of ataxia that is acquired or secondary to another medical condition including but not limited to, alcoholism, head injury, multiple sclerosis, olivopontocerebellar atrophy, multiple system atrophy, or stroke.
- 10. Prior history of drug-induced liver injury (DILI) and/or laboratory results at screening that indicate inadequate liver function (e.g. alanine aminotransferase [ALT], aspartate aminotransferase [AST], gamma-glutamyl transferase [GGT] > 2 times the upper limit of normal [x ULN] and/or total bilirubin level > 2 x ULN).
- 11. Laboratory results at screening that indicate inadequate renal function (e.g. estimated creatinine clearance of < 60 mL/min calculated by the Cockcroft and Gault formula).
- 12. Any current cardiovascular disease or abnormality on 12-lead ECG at screening that, in the investigator’s opinion, is clinically significant and could be a potential safety risk to the participant.
- 13. Any current psychiatric, neurological, or cognitive disorder that, in the investigator’s opinion, may interfere with the participant’s ability to provide informed consent or appropriately complete the study’s safety or efficacy assessments.
- 14. Significant suicide risk as indicated by a “yes” response to question #4 or #5 under Suicidal Ideation in the past 6 months or any “yes” response under Suicidal Behavior in the past 3 years on the Columbia Suicide Severity Rating Scale (C-SSRS) during the screening visit.
- 15. Any other medical condition or abnormal finding at screening that, in the investigator’s opinion, could confound collection or interpretation of safety or efficacy data or be a potential safety risk to the participant.
- 2. A score of 4 on any 1 of the 4 items that comprise the m-SARA.
- 3. Current participation in another clinical trial or completed participation in an interventional trial less than 30 days prior to the screening visit (90 days for a biological treatment).
- 4. Current diagnosis and/or healthcare professional-recommended treatment (medication and/or diet) of diabetes mellitus type 1 or type 2.
- 5. Hemoglobin A1c (HbA1c) ≥ 6.5% at the screening visit.
- 6. Prior treatment with SLS-005, any other IV trehalose formulation, or known hypersensitivity to trehalose.
- 7. Pregnant or breastfeeding.
- 8. History of alcohol or drug abuse within the last 2 years.
- 9. Chronic liver disease including Hepatitis B; Hepatitis C unless successful curative treatment is documented; HIV infection.
The study team makes the final eligibility decision.
Where it's taking place
- China
- Australia
- Brazil
- United Kingdom
- Korea, Republic of
- United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include China; Australia; Brazil; United Kingdom; Korea, Republic of; United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.